QoL with refractory diffuse large B-cell lymphoma may improve with tisagenlecleucel
February 25, 2020
A new study, led by Richard Maziarz, M.D., finds that adult lymphoma patients treated with CAR-T therapy showed marked improvement on a variety of self-reported quality of life measures. He says: “The need for patient-reported outcomes is increasingly being recognized in clinical trials in patients with cancer... We never will really understand if living 10 years with debility would be acceptable or unacceptable to a patient, unless we (ask about and) pursue the patient's personal goals of care.”